These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 20601874)

  • 1. Will there be a role for genotyping in warfarin therapy?
    Gandara E; Wells PS
    Curr Opin Hematol; 2010 Sep; 17(5):439-43. PubMed ID: 20601874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmocogenomics of warfarin: closing in on personalized medicine.
    Rettie AE; Tai G
    Mol Interv; 2006 Aug; 6(4):223-7. PubMed ID: 16960144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetic-based dosing of warfarin.
    Med Lett Drugs Ther; 2008 May; 50(1286):39-40. PubMed ID: 18487958
    [No Abstract]   [Full Text] [Related]  

  • 4. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.
    You JH; Tsui KK; Wong RS; Cheng G
    Clin Pharmacol Ther; 2009 Nov; 86(5):540-7. PubMed ID: 19571807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of genotype-guided warfarin dosing for patients with atrial fibrillation.
    Patrick AR; Avorn J; Choudhry NK
    Circ Cardiovasc Qual Outcomes; 2009 Sep; 2(5):429-36. PubMed ID: 20031873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic influences on the response to warfarin.
    Kamali F
    Curr Opin Hematol; 2006 Sep; 13(5):357-61. PubMed ID: 16888441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current pharmacogenetic developments in oral anticoagulation therapy: the influence of variant VKORC1 and CYP2C9 alleles.
    Oldenburg J; Bevans CG; Fregin A; Geisen C; Müller-Reible C; Watzka M
    Thromb Haemost; 2007 Sep; 98(3):570-8. PubMed ID: 17849045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anticoagulation with warfarin].
    Schinzel H; Nitschmann S
    Internist (Berl); 2009 Aug; 50(8):1026-8. PubMed ID: 19499193
    [No Abstract]   [Full Text] [Related]  

  • 9. [Warfarin resistance and related pharmacogenetic information].
    Takahashi H
    Brain Nerve; 2008 Nov; 60(11):1365-71. PubMed ID: 19069171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now.
    Rosove MH; Grody WW
    Ann Intern Med; 2009 Aug; 151(4):270-3, W95. PubMed ID: 19687493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic testing for warfarin dosing? Not yet ready for prime time.
    Bussey HI; Wittkowsky AK; Hylek EM; Walker MB
    Pharmacotherapy; 2008 Feb; 28(2):141-3. PubMed ID: 18225960
    [No Abstract]   [Full Text] [Related]  

  • 12. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study).
    Epstein RS; Moyer TP; Aubert RE; O Kane DJ; Xia F; Verbrugge RR; Gage BF; Teagarden JR
    J Am Coll Cardiol; 2010 Jun; 55(25):2804-12. PubMed ID: 20381283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of warfarin pharmacogenetic testing in clinical practice.
    Tan GM; Wu E; Lam YY; Yan BP
    Pharmacogenomics; 2010 Mar; 11(3):439-48. PubMed ID: 20402581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Application of warfarin pharmacogenetics].
    Tomek A; Mat'oska V; Kumstýrfová T; Táborský L
    Vnitr Lek; 2009 Jun; 55(6):565-9. PubMed ID: 19662888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacogenetics of vitamin K antagonists: useful or hype?
    Lippi G; Franchini M; Favaloro EJ
    Clin Chem Lab Med; 2009; 47(5):503-15. PubMed ID: 19397481
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of commercial platforms for rapid genotyping of polymorphisms affecting warfarin dose.
    King CR; Porche-Sorbet RM; Gage BF; Ridker PM; Renaud Y; Phillips MS; Eby C
    Am J Clin Pathol; 2008 Jun; 129(6):876-83. PubMed ID: 18480003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients.
    Meckley LM; Wittkowsky AK; Rieder MJ; Rettie AE; Veenstra DL
    Thromb Haemost; 2008 Aug; 100(2):229-39. PubMed ID: 18690342
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design.
    van Schie RM; Wadelius MI; Kamali F; Daly AK; Manolopoulos VG; de Boer A; Barallon R; Verhoef TI; Kirchheiner J; Haschke-Becher E; Briz M; Rosendaal FR; Redekop WK; Pirmohamed M; Maitland van der Zee AH
    Pharmacogenomics; 2009 Oct; 10(10):1687-95. PubMed ID: 19842940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The long and winding road to warfarin pharmacogenetic testing.
    Ginsburg GS; Voora D
    J Am Coll Cardiol; 2010 Jun; 55(25):2813-5. PubMed ID: 20579536
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.